Ask sales for the lot-numbered COA. Net peptide content, RP-HPLC, ESI-MS, or other results appear only when they are part of that batch's agreed analytical scope.

Batch COA records net peptide content when included in the agreed specification.

Reading a Peptide HPLC Trace — A 5-Minute Field Guide for Bench Scientists. Read our briefing →

On reading HPLC traces. Read →

B7-33

Name: B7-33
Brand: Lyochem
SKU: b7-33

Single-chain relaxin analog · RXFP1 agonist

Available by request≥ 99.0%CAS 1818415-56-3Tissue-Repair Peptides

Lyochem primary owner

B7-33 for research-standard qualification and analytical packet review

This Lyochem page is the primary SEO owner for research labs, CROs, and method-development teams qualifying B7-33 as a documented research-standard lot. The page should answer whether the buyer can review HPLC purity, identity confirmation, lot continuity, stability handling, and assay-fit documentation before ordering.

Use this page when the buyer needs an analytical packet, sequence or identity evidence, reference-lot continuity, or method-development support.
Request the analytical packet when the decision is assay replication, internal method transfer, or research-vendor qualification.
Pharmacy release-documentation procurement and broad distributor / OEM sourcing where catalog economics dominate are separate buying contexts served elsewhere.

Overview

B7-33 is a 27-residue single-chain analog of native relaxin-2 (H2-relaxin) that keeps the RXFP1-agonist activity of the parent hormone while dispensing with its disulfide-linked two-chain architecture. It behaves as a biased RXFP1 agonist, favoring signaling through the ERK1/2 arm downstream of the receptor while engaging the cAMP arm only weakly; the developers reasoned this bias could deliver relaxin's anti-fibrotic and tissue-remodeling actions without the dose-limiting cardiovascular effects tied to balanced full agonism. Lyochem supplies B7-33 as a lyophilized 27-residue reference standard at ≥99.0% HPLC. Because it is a linear single chain carrying no disulfide bridges, it is far more tractable to synthesize than the disulfide-bonded native relaxin heterodimer, a practical dividend of the biased-agonist design that sits alongside its pharmacology. Where included in the agreed analytical scope, the batch record can report RP-HPLC purity and mass-spectrometric identity, with sequence verification supplied on request. Fill sizes of 2 mg and 10 mg serve typical fibrosis, cardiovascular, and tissue-remodeling research models.

Applications & buyer fit

What research workflows this standard is sourced for

Repair peptides — BPC-157, TB-500, B7-33, PEG-MGF — ship primarily to research laboratories. The applicable batch COA records the tests actually completed. Tandem-MS sequence evidence is an additional agreed scope when the buyer's written procedure requires it, not a blanket requirement to repeat release testing.

Research-buyer fit

Academic Laboratories

Universities, medical schools, and government research institutes qualifying a reference standard for a method-development or in vivo workflow.

Standard lot documentation

Per-lot Certificate of Analysis
Every release ships with its own batch-specific CoA — identity, purity, and the analytical scope agreed at quote stage, tied to the exact lot you receive.
Sample COA on request
Review a representative batch CoA before you order, so you can confirm the packet matches what your method or sponsor audit needs.
Research Use Only · B2B supply
Supplied strictly as a research reagent to research institutions — not a finished dosage form and not for human administration. Buyer qualification runs at the inquiry stage.

Specifications

CAS: 1818415-56-3
Sequence: VIKLSGRELVRAQIAISGMSTWSKRSL
Appearance: White to off-white lyophilized powder
Purity (HPLC): ≥ 99.0%
Strength: 2 mg – 10 mg
Packaging: 10 vials/box · base pack (multiples of 10)
MOQ: On request
Lead time: 14–21 days
Storage: -20°C, protect from light

Documentation available on request

Lot-specific Certificate of Analysis (CoA)
RP-HPLC chromatogram with peak integration
ESI-MS identity confirmation (±0.5 Da)
Sequence verification by LC-MS/MS
Water content by Karl Fischer
SDS / MSDS
Counter-ion analysis (acetate vs TFA)
Solubility / reconstitution guidance
Stability data at −20 °C on request

Regulatory note

Sold for Research Use Only under the receiving laboratory's institutional and jurisdictional regulations. Not a finished dosage form, not labelled for human administration, not for in-vitro diagnostic use. For in vivo workflows, request bacterial-endotoxin and microbial-limit testing on the specific lot at quote stage.

Frequently asked questions

What evidence can support B7-33 identity?▾

Start with the COA matched to the offered batch. If the buyer's written procedure needs added RP-HPLC, ESI-MS, or LC-MS/MS evidence, confirm availability and define the method, acceptance rule, sample, reporting, timing, and cost before quotation. The linear sequence has no disulfide-regiochemistry question, but no fixed analytical panel is implied for every lot.

How should net peptide content and counter-ion be handled for reproducible B7-33 assays?▾

Review the matching batch COA to see which content, counter-ion, or water results were actually recorded. If the buyer's calculation requires additional measurements, agree that scope with sales before quotation rather than assuming those items are standard on every COA.

Related peptides

Buyers who view B7-33 also ask about:

15-mer

BPC-157

≥99.0%

Body Protection Compound 15-mer

CAS: 137525-51-0
Vial: 2 mg–20 mg

MOQ on requestView details →

43-mer

TB-500

≥99.0%

Thymosin β4 fragment

CAS: 77591-33-4
Vial: 2 mg–10 mg

MOQ on requestView details →

See full catalog

B7-33

Single-chain relaxin analog · RXFP1 agonist

Available by request≥ 99.0%CAS 1818415-56-3Tissue-Repair Peptides

Lyochem primary owner

B7-33 for research-standard qualification and analytical packet review

Use this page when the buyer needs an analytical packet, sequence or identity evidence, reference-lot continuity, or method-development support.
Request the analytical packet when the decision is assay replication, internal method transfer, or research-vendor qualification.
Pharmacy release-documentation procurement and broad distributor / OEM sourcing where catalog economics dominate are separate buying contexts served elsewhere.

Overview

Applications & buyer fit

What research workflows this standard is sourced for

Research-buyer fit

Academic Laboratories

Universities, medical schools, and government research institutes qualifying a reference standard for a method-development or in vivo workflow.

Standard lot documentation

Per-lot Certificate of Analysis
Every release ships with its own batch-specific CoA — identity, purity, and the analytical scope agreed at quote stage, tied to the exact lot you receive.
Sample COA on request
Review a representative batch CoA before you order, so you can confirm the packet matches what your method or sponsor audit needs.
Research Use Only · B2B supply
Supplied strictly as a research reagent to research institutions — not a finished dosage form and not for human administration. Buyer qualification runs at the inquiry stage.

Specifications

CAS: 1818415-56-3
Sequence: VIKLSGRELVRAQIAISGMSTWSKRSL
Appearance: White to off-white lyophilized powder
Purity (HPLC): ≥ 99.0%
Strength: 2 mg – 10 mg
Packaging: 10 vials/box · base pack (multiples of 10)
MOQ: On request
Lead time: 14–21 days
Storage: -20°C, protect from light

Documentation available on request

Lot-specific Certificate of Analysis (CoA)
RP-HPLC chromatogram with peak integration
ESI-MS identity confirmation (±0.5 Da)
Sequence verification by LC-MS/MS
Water content by Karl Fischer
SDS / MSDS
Counter-ion analysis (acetate vs TFA)
Solubility / reconstitution guidance
Stability data at −20 °C on request

Regulatory note

Frequently asked questions

What evidence can support B7-33 identity?▾

How should net peptide content and counter-ion be handled for reproducible B7-33 assays?▾

Related peptides

Buyers who view B7-33 also ask about:

15-mer

BPC-157

≥99.0%

Body Protection Compound 15-mer

CAS: 137525-51-0
Vial: 2 mg–20 mg

MOQ on requestView details →

43-mer

TB-500

≥99.0%

Thymosin β4 fragment

CAS: 77591-33-4
Vial: 2 mg–10 mg

MOQ on requestView details →

See full catalog